Qtrex Quantum Ltd. · NASDAQ:QTEX
Qtrex Quantum — Inspira Technologies OXY B.H.N. — Investor Presentation (June 2024)
10 slides from Qtrex Quantum's investor presentation, Jun 20, 2024
Slide 1: Empowered Breathing Without Lungs
EMPOWERED BREATHING WITHOUT LUNGS Conference Call June 2024 InspIra
Slide 2: Forward Looking Statement Disclaimer
Forward Looking Statement Disclaimer This presentation contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject
Slide 3: Disclaimers
Disclaimers The reference to INSPIRA™ ART is a series of planned devices. The use of the term INSPIRA™ ART or INSPIRA™ ART (Gen2) can refer to the INSPIRA™ ART5OO and are all referring to the same device. INSPIRA™ ART100 was previously known as the ALICE™. Mechanical Ventilation/Ventilators or MV re
Slide 4: Discover INSPIRA ART (Gen 2)
INspIra OXYGEN SATURATION 96% ° CARDIAC OUTPUT §.3L/min PRESSURE METERS Q 2D eta} Fy 50 (nntol Discover INSPIRA™ ART (Gen 2) A novel technology to deliver oxygen straight into the blood, ultimately becoming a form of life support while patients are awake, with the goal to eliminate the need for mech
Slide 5: Technology and innovation drive each other
Technology and innovation drive each other Technology Technology Technology Treating patients Dissolves Oxygen Monitors patient z while awake straight into the condition in 3 blood real-time : The tir umes certain approvals by regulatory and or other authorizing authorities and are ange. There is in
Slide 6: Business Strategy
Business Strategy $11 Billion $19 Billion Perfusion Systems Market Mechanical Ventilation Market é FDA 510(k) Cleared Gent Gen2 INSPIRA™ ART100 INSPIRA™ ART (Gen2) assumes certain approvals by regulatory and or other authorizing authori and are subject to change. There is inherent regulatory process
Slide 7: Leveraging proven capabilities from INSPIRA ART100 to Gen 2
$1 Billion Perfusion Systems Market FDA 510(k) Cleared Gent INSPIRA™ ART10O Leveraging on proven capabilities to enable the leap from INSPIRA™ ART100 to INSPIRA™ ART(Gen 2) ¢ INSPIRA™ ART100 R&D success story is indicative of future potential breakthrough with INSPIRA™ ART (Gen 2) ¢ Regulatory succe
Slide 8: Business Goals (2024-2025)
Business Goals (2024-2025) Use INSPIRA™ ART100 as penetration model for INSPIRA ART (Gen2) . sw * Product marketing Z, Multiple site deployment in leading hospitals * Develop customer/user base to receive the HYLA followed by the INSPIRA™ ART (Gen 2) INSPIRA™ ARTIOO == * FDA Submission for HYLA™ Blo
Slide 9: Company to aggressively promote INSPIRA ART100 in the U.S.
Company to aggressively promote INSPIRA™ ART100 in the U.S. and additional markets following FDA clearance, as well as accelerate plans for game changing INSPIRA™ ART (Gen2) INSPIRA™ ART100 InspIra
Slide 10: Thank You
Nasda Thank You INsSpIra
Inspira Technologies OXY B.H.N. — Investor Presentation (June 2024) on 6ix